New York, United States
ENB Therapeutics, founded in 2015, is a pioneering player in the Biotechnology and Health and Wellness sectors, headquartered in the United States. The company is on a mission of "Overcoming Immunotherapy resistance". They are developing breakthrough therapies aiming to overcome drug resistance in over 50% of cancer patients.
Their flagship product, ENB-001, an innovative endothelin B receptor (ETBR) inhibitor, has showcased promising results in preclinical trials, significantly reducing tumor growth and extending survival in cancer models. In 2016, the FDA granted the Orphan Drug Designation to ENB-001, which enhances market exclusivity and strengthens intellectual property rights. The product’s combination of cost-effective and swift developmental paths targets proof of concept within 18 months post-financing.
The company’s last significant financial milestone was a Series A investment made by New York Ventures on 03 January 2022. This strategic investment positions ENB Therapeutics as a strong contender in the expanding immunotherapy market, with prospects for indication expansions using their companion diagnostic technology.
